117 related articles for article (PubMed ID: 9774962)
1. Intensifying induction therapy in acute myeloid leukemia by an infusional chemotherapy schedule.
Friedenberg WR
Cancer Invest; 1998; 16(7):542-3. PubMed ID: 9774962
[No Abstract] [Full Text] [Related]
2. Induction chemotherapy for acute myelogenous leukemia.
Kalaycio M
Curr Hematol Rep; 2005 Jan; 4(1):49-50. PubMed ID: 15610659
[No Abstract] [Full Text] [Related]
3. New agents in the treatment of acute myeloid leukemia.
Wiernik PH
Semin Hematol; 1991 Jul; 28(3 Suppl 4):95-8. PubMed ID: 1780763
[No Abstract] [Full Text] [Related]
4. Outcome after induction chemotherapy for older patients with acute myeloid leukemia is not improved with mitoxantrone and etoposide compared to cytarabine and daunorubicin: a Southwest Oncology Group study.
Anderson JE; Kopecky KJ; Willman CL; Head D; O'Donnell MR; Luthardt FW; Norwood TH; Chen IM; Balcerzak SP; Johnson DB; Appelbaum FR
Blood; 2002 Dec; 100(12):3869-76. PubMed ID: 12393614
[TBL] [Abstract][Full Text] [Related]
5. Intensified induction chemotherapy with high dose cytarabine and etoposide for acute myeloid leukemia: a review and updated results of the Australian Leukemia Study Group.
Bishop JF; Matthews JP; Young GA; Bradstock K; Lowenthal RM
Leuk Lymphoma; 1998 Jan; 28(3-4):315-27. PubMed ID: 9517503
[TBL] [Abstract][Full Text] [Related]
6. No beneficial effect from addition of etoposide to daunorubicin, cytarabine, and 6-mercaptopurine in individualized induction therapy of adult acute myeloid leukemia: the JALSG-AML92 study. Japan Adult Leukemia Study Group.
Miyawaki S; Tanimoto M; Kobayashi T; Minami S; Tamura J; Omoto E; Kuriyama K; Hatake K; Saito K; Kanamaru A; Oh H; Ohtake S; Asou N; Sakamaki H; Yamada O; Jinnai I; Tsubaki K; Takeyama K; Hiraoka A; Matsuda S; Takahashi M; Shimazaki C; Adachi K; Kageyama S; Ohno R
Int J Hematol; 1999 Aug; 70(2):97-104. PubMed ID: 10497848
[TBL] [Abstract][Full Text] [Related]
7. [The results of 2 and 1/2 years of work of the Russian Multicenter Trial on the Treatment of Acute Myeloid Leukemias in Adults].
Savchenko VG; Parovichnikova EN; Gliasova GA; Isaev VG; Kulikov SM; Tikhonova LIu; Cherepanova VV; Rekhtman GB; Medvedeva NV; Kaporskaia TS
Ter Arkh; 1995; 67(7):8-12. PubMed ID: 7482315
[No Abstract] [Full Text] [Related]
8. [The current chemotherapy of acute myeloid leukemias in adults].
Poddubnaia IV; Perilov AA
Ter Arkh; 1993; 65(7):86-9. PubMed ID: 8211791
[No Abstract] [Full Text] [Related]
9. [The results of a multicenter cooperative study on treating acute myeloid leukemias in adults].
Savchenko VG; Parovichnikova EN; Kliasova GA; Isaev VG; Kulikov SM; Tikhonova LIu; Cherepanova VV; Rekhtman GB; Medvedeva NV; Kaporskaia TS
Ter Arkh; 1994; 66(7):11-7. PubMed ID: 7985120
[No Abstract] [Full Text] [Related]
10. The treatment of older adult patients with acute myeloid leukemia by triple infusion chemotherapy.
Friedenberg WR; Miller HJ; Marx JJ; Schloesser LL; Reding DJ; Mazza JJ; Hocking WG; Mercier RJ; Raich PC; Cassileth PA
Am J Clin Oncol; 1995 Apr; 18(2):105-10. PubMed ID: 7900701
[TBL] [Abstract][Full Text] [Related]
11. Intensive post-remission therapy with Ara-C in adults with acute myeloid leukemia: initial results of a CALGB phase III trial. The Cancer and Leukemia Group B.
Mayer RJ; Davis RB; Schiffer CA; Berg DT; Sarno E; Frei E
Leukemia; 1992; 6 Suppl 2():66-7. PubMed ID: 1578945
[No Abstract] [Full Text] [Related]
12. Parallel phase I studies of daunorubicin given with cytarabine and etoposide with or without the multidrug resistance modulator PSC-833 in previously untreated patients 60 years of age or older with acute myeloid leukemia: results of cancer and leukemia group B study 9420.
Lee EJ; George SL; Caligiuri M; Szatrowski TP; Powell BL; Lemke S; Dodge RK; Smith R; Baer M; Schiffer CA
J Clin Oncol; 1999 Sep; 17(9):2831-9. PubMed ID: 10561359
[TBL] [Abstract][Full Text] [Related]
13. Comparison of fludarabine-containing salvage chemotherapy regimens for relapsed/refractory acute myelogenous leukemia.
Thomas MB; Koller C; Yang Y; Shen Y; O'Brien S; Kantarjian H; Davis J; Estey E
Leukemia; 2003 May; 17(5):990-3. PubMed ID: 12750721
[No Abstract] [Full Text] [Related]
14. Oral induction and consolidation of acute myeloid leukemia with etoposide, 6-thioguanine, and idarubicin (ETI) in elderly patients: a randomized comparison with 5-day TAD. Finnish Leukemia Group.
Ruutu T; Almqvist A; Hallman H; Honkanen T; Järvenpää E; Järventie G; Koistinen P; Koivunen E; Lahtinen R; Lehtinen M
Leukemia; 1994 Jan; 8(1):11-5. PubMed ID: 8289475
[TBL] [Abstract][Full Text] [Related]
15. Double intensive consolidation chemotherapy in adult acute myeloid leukemia.
Harousseau JL; Milpied N; Briere J; Desablens B; Leprise PY; Ifrah N; Gandhour B; Casassus P
J Clin Oncol; 1991 Aug; 9(8):1432-7. PubMed ID: 2072146
[TBL] [Abstract][Full Text] [Related]
16. Dose escalation studies of cytarabine, daunorubicin, and etoposide with and without multidrug resistance modulation with PSC-833 in untreated adults with acute myeloid leukemia younger than 60 years: final induction results of Cancer and Leukemia Group B Study 9621.
Kolitz JE; George SL; Dodge RK; Hurd DD; Powell BL; Allen SL; Velez-Garcia E; Moore JO; Shea TC; Hoke E; Caligiuri MA; Vardiman JW; Bloomfield CD; Larson RA;
J Clin Oncol; 2004 Nov; 22(21):4290-301. PubMed ID: 15514371
[TBL] [Abstract][Full Text] [Related]
17. The impact of early intensive therapy on event-free survival (EFS) in children with acute myeloid leukemia (AML).
Weinstein H; Ravindranath Y; Krischer J; Steuber P; Civin C; Gresik M; Vietti T
Leukemia; 1992; 6 Suppl 2():52-4. PubMed ID: 1578941
[No Abstract] [Full Text] [Related]
18. Comparison of 'sequential' versus 'standard' chemotherapy as re-induction treatment, with or without cyclosporine, in refractory/relapsed acute myeloid leukaemia (AML): results of the UK Medical Research Council AML-R trial.
Liu Yin JA; Wheatley K; Rees JK; Burnett AK;
Br J Haematol; 2001 Jun; 113(3):713-26. PubMed ID: 11380463
[TBL] [Abstract][Full Text] [Related]
19. Mitoxantrone and cytarabine versus daunorubicin and cytarabine in previously untreated patients with acute myeloid leukemia.
Wahlin A; Hörnsten P; Hedenus M; Malm C
Cancer Chemother Pharmacol; 1991; 28(6):480-3. PubMed ID: 1934252
[TBL] [Abstract][Full Text] [Related]
20. P-glycoprotein (Pgp) modulation in untreated acute myeloid leukemia (AML): Cancer and Leukemia Group B (CALGB) trials in younger and older adults.
Kolitz JE; George SL; Baer MR; Lee EJ; Bloomfield CD; Larson RA;
Ann Hematol; 2004; 83 Suppl 1():S103-4. PubMed ID: 15124695
[No Abstract] [Full Text] [Related]
[Next] [New Search]